|
Nimotuzumab-pancreatic cancer-adults-Phase IV. |
30/04/2017 |
CIM |
|
Safety and effectiveness of SURFACEN® combined with the conventional therapy, in the treatment of ARDS in pediatrics. National extension |
29/09/2017 |
CENSA |
|
Heberon Alfa R in COVID-19 |
29/05/2020 |
MINSAP_AM |
|
Predictor of response with CIMAvax EGF© in NSCLC Phase III |
29/01/2016 |
CIM |
|
Expanded clinical use of NeuralCIM in mild to moderate Alzheimer's disease (REAL study) |
28/09/2026 |
CIM |
|
Oral OLEOZON® in the endodontic treatment of teeth with pulp necrosis. Phase II |
27/05/2026 |
PSurMoron |
|
Evaluation of Clinical Performance of INFANTIX in a Maternity Hospital |
27/04/2022 |
CNEURO |
|
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. |
26/05/2014 |
CIM |
|
Stem cell assisted centrifugal fat transfer |
26/03/2021 |
HHA |
|
Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma |
24/08/2026 |
CIM |
|
SURFACEN in ARDS. Adults. Phase IV |
24/06/2015 |
CENSA |
|
Phase III clinical trial: Dermofural®. Mild infection in diabetic foot ulcer |
24/04/2023 |
CBQ |
|
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus |
23/12/2016 |
CIM |
|
SOBERANA PEDIATRIA CLINICA 1 |
23/07/2021 |
FINLAY |
|
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. |
23/05/2014 |
CIM |
|
Interferon Combination in basal cell carcinoma (InCarbacel-IV study) |
22/08/2013 |
CIGB |
|
VIDA study |
22/06/2020 |
CIGB |
|
Evaluation of the synergistic effect of sequential administration of two immunostimulant products: Immuno-1 and Immuno-2 for the stimulation of the immune response in older adults. Exploratory study |
22/05/2020 |
FINLAY |
|
VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 |
22/05/2020 |
FINLAY |
|
Totally Laparoscopic Hysterectomy with Single-Port Access. Validation of a new technique in Cuba. |
22/04/2014 |
CNCMA |
